Plain-English translation of NCT06789757 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding memantine to the standard two-drug combination of and can help treat hepatocellular carcinoma (advanced liver cancer). Researchers want to see if this three-drug approach works better than the two-drug treatment alone. You would receive all three medications together in repeated treatment cycles over six months.
Current two-drug treatments help some patients with advanced liver cancer, but researchers believe adding this third medication might improve how well the treatment works by targeting a different pathway in cancer cells.
You likely qualify if…
You likely don't qualify if…
You would receive all three medications as injections or infusions in 21-day treatment cycles, continuing for six months. You would visit the clinic regularly for each cycle to receive treatment and have your blood work and imaging checked. At each visit, you would also complete surveys about how you are feeling and how the cancer is affecting your quality of life. The study team will monitor you closely throughout to watch for side effects and see how well the treatment is working.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States